Orion Group

Activities: Manufacturing Ingredients Analysis Pharmaceutical Dietary supplements Active Nutrition Food

Trending Articles

  1. Sanofi completes acquisition of Blueprint Medicines Sanofi announces the completion of its acquisition of Blueprint Medicines Corporation, adding to its portfolio a commercialised medicine and the expertise of a company...
  2. RCPE and InSilicoTrials to digitalise and accelerate the development of pharmaceutical manufacturing processes RCPE and InSilicoTrials have agreed to an exclusive partnership to commercialise the XPS simulation software. Specifically developed for pharmaceutical applications, XPS allows...
  3. Weight loss drugs such as Ozempic may prevent stroke and reduce brain injury related complications Three studies presented at the Society of NeuroInterventional Surgery's (SNIS) 22nd Annual Meeting discussed whether using GLP-1 inhibitors could lessen the impacts of stroke...
  4. You need to be a subscriber to read this article.
    Click here to find out more.
    How onco-HPAPI manufacturing is adapting to a new era The oncology landscape is undergoing a quiet but powerful shift. Pharmaceutical companies, once focused primarily on novel compounds, are now increasingly exploring repurposing...
  5. Almost 60% of workplace injuries from harmful substances are burns Chemical burns continue to be the leading type of non-fatal injury caused by exposure to or contact with harmful substances in workplaces across Great Britain

Upcoming event

POWTECH

23-25 September 2025 | Exhibition | Nuremberg, Germany See all

Related Content

Finance

Orion to open new biologics R&D centre in Cambridge, UK, in 2025

Biologics are the fastest growing segment in pharma, representing huge opportunities for new innovative treatments
Sustainability

Orion’s near-term climate targets approved by the Science Based Targets initiative

Orion Corporation is proud to announce that the Science Based Targets initiative (SBTi) has validated its near-term science-based targets
Research & Development

Orion and Glykos announce research collaboration and licensing agreement to develop next-generation ADCs

Orion Corporation and Glykos Finland Oy have entered into a research collaboration and licensing agreement to develop next-generation antibody-drug conjugates (ADCs)
Research & Development

Orion and MSD announce two Phase III trials to evaluate ODM-208/MK5684 in patients with metastatic castration-resistant prostate cancer

OMAHA1 and OMAHA2a are the first Phase III trials to be initiated for ODM-208/MK5684
Distribution

Orion and Amneal enter distribution partnership

The initial portfolio will include a mix of generic products commercially available in the US today
Research & Development

Orion and MSD announce global collaboration to develop and commercialise ODM-208

Agreement strengthens and complements MSD’s oncology pipeline
Distribution

Orion to commercialise Jemincare pain treatment

Under the agreement, Orion will receive global development and commercialisation rights outside of mainland China, Hong Kong, Macau and Taiwan
Subscribe now